{"id":6707,"date":"2023-10-17T16:12:00","date_gmt":"2023-10-17T16:12:00","guid":{"rendered":"https:\/\/www.waters.com\/blog\/?p=6707"},"modified":"2026-01-21T11:36:07","modified_gmt":"2026-01-21T11:36:07","slug":"is-it-time-to-re-evaluate-u-s-pharmacopeia-standards-exploring-y-site-pediatric-drug-administration-compatibility","status":"publish","type":"post","link":"https:\/\/www.waters.com\/blog\/is-it-time-to-re-evaluate-u-s-pharmacopeia-standards-exploring-y-site-pediatric-drug-administration-compatibility\/","title":{"rendered":"Is it Time to Re-Evaluate U.S. Pharmacopeia Standards? Exploring Y-site Pediatric Drug Administration Compatibility"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Navigating the complex landscape of\u00a0pediatric\u00a0healthcare, particularly when it involves administering intravenous (IV) medication to children, brings about a unique set of difficulties. The task becomes even more daunting when dealing with critically ill patients who\u00a0frequently\u00a0require extensive IV drugs to\u00a0maintain\u00a0homeostasis.\u00a0<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full\"><img decoding=\"async\" width=\"600\" height=\"426\" src=\"https:\/\/www.waters.com\/blog\/wp-content\/uploads\/image-30.png\" alt=\"IV in child's hand\" class=\"wp-image-6711\" srcset=\"https:\/\/www.waters.com\/blog\/wp-content\/uploads\/image-30.png 600w, https:\/\/www.waters.com\/blog\/wp-content\/uploads\/image-30-300x213.png 300w\" sizes=\"(max-width: 600px) 100vw, 600px\" \/><\/figure>\n<\/div>\n\n\n<p class=\"wp-block-paragraph\">To put it into perspective, an infant in a neonatal intensive care unit might receive an average of 8.5 IV drugs during a single admission, while children in a\u00a0pediatric\u00a0intensive care unit can receive a staggering number of up to 49 IV medications.<sup>1<\/sup>\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Due to the challenges associated with\u00a0pediatric\u00a0patients, medications are typically prepared and administered at different concentrations compared to adult patients. This is largely because infants have higher nutritional needs. However, this process is not without risks. Incompatible IV medications can produce particles, invisible to the naked eye. Recent studies have shown that infants undergoing multidrug IV therapies can potentially be exposed to up to 85,000 such subvisible particles each day.<sup>1<\/sup>\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The impact of these particles on\u00a0pediatric\u00a0patients can be profound, leading to serious complications like pulmonary dysfunction, cardiovascular arrest, and multiorgan failure. Further, these particles may negatively affect immune responses, adding another layer of risk. The danger of unintentionally administering these particles increases when co-administering untested medications for physical compatibility.<sup>1<\/sup>\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For this reason, researchers set out to evaluate the physical intravenous Y-site compatibility of 29 combinations of medications at concentrations commonly used in\u00a0pediatrics\u00a0using both conventional and innovative techniques.<sup>1\u202f\u202f<\/sup>In a\u202f<a href=\"https:\/\/meridian.allenpress.com\/jppt\/article\/28\/1\/84\/490592\/Physical-Compatibility-of-Y-site-Pediatric-Drug\" target=\"_blank\" rel=\"noreferrer noopener\">study<\/a>\u202fpublished in\u202f<em>The Journal of\u00a0Pediatric\u00a0Pharmacology and Therapeutics<\/em>, subvisible\u202f<a href=\"https:\/\/www.waters.com\/nextgen\/global\/applications\/biopharma-and-pharma\/protein-therapies\/particle-counting-and-identification.html\" target=\"_blank\" rel=\"noreferrer noopener\">particle analysis<\/a>\u202fwas performed using\u202f<a href=\"https:\/\/www.waters.com\/nextgen\/global\/applications\/biopharma-and-pharma\/protein-therapies\/particle-counting-and-identification.html\" target=\"_blank\" rel=\"noreferrer noopener\">Backgrounded Membrane Imaging (BMI)<\/a>, a high-contrast imaging technique on\u202fthe\u00a0<a href=\"https:\/\/www.waters.com\/nextgen\/global\/products\/particle-analyzers.html\">Aura\u00a0System<\/a>. With the ability to test 96 samples in less than two hours,\u00a0it\u2019s\u00a0a valuable tool for drug development.\u00a0<\/p>\n\n\n<style>.wp-block-kadence-spacer.kt-block-spacer-6707_723ee3-cf .kt-block-spacer{height:60px;}.wp-block-kadence-spacer.kt-block-spacer-6707_723ee3-cf .kt-divider{border-top-width:1px;height:1px;border-top-color:#eee;width:80%;border-top-style:solid;}<\/style>\n<div class=\"wp-block-kadence-spacer aligncenter kt-block-spacer-6707_723ee3-cf\"><div class=\"kt-block-spacer kt-block-spacer-halign-center\"><hr class=\"kt-divider\"\/><\/div><\/div>\n\n\n<style>.wp-block-kadence-advancedheading.kt-adv-heading6707_441897-69, .wp-block-kadence-advancedheading.kt-adv-heading6707_441897-69[data-kb-block=\"kb-adv-heading6707_441897-69\"]{font-style:normal;}.wp-block-kadence-advancedheading.kt-adv-heading6707_441897-69 mark.kt-highlight, .wp-block-kadence-advancedheading.kt-adv-heading6707_441897-69[data-kb-block=\"kb-adv-heading6707_441897-69\"] mark.kt-highlight{font-style:normal;color:#f76a0c;-webkit-box-decoration-break:clone;box-decoration-break:clone;padding-top:0px;padding-right:0px;padding-bottom:0px;padding-left:0px;}.wp-block-kadence-advancedheading.kt-adv-heading6707_441897-69 img.kb-inline-image, .wp-block-kadence-advancedheading.kt-adv-heading6707_441897-69[data-kb-block=\"kb-adv-heading6707_441897-69\"] img.kb-inline-image{width:150px;vertical-align:baseline;}<\/style>\n<h2 class=\"kt-adv-heading6707_441897-69 wp-block-kadence-advancedheading\" data-kb-block=\"kb-adv-heading6707_441897-69\">Understanding Particulate Matter in Injectable Products\u00a0<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Pediatric\u00a0patients often receive multiple IV medications via a Y-site connection, due to difficulties with securing reliable vascular access. However, this can lead to medication interaction and potential particle formation. This puts healthcare providers in a tough position\u2014risking co-administering medications without compatibility data or dealing with the challenges associated with\u00a0additional\u00a0vascular access.<sup>1<\/sup><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Given the slow infusion rates used in\u00a0pediatric\u00a0patients, IV medications can interact with each other for extended periods before entering the bloodstream. Even with an inline filter, substantial mixing of medications can occur downstream of the filter, potentially leading to particle formation if the medications are physically incompatible.<sup>1<\/sup><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Traditional methods for assessing particulate matter in injectable products, as outlined by the US Pharmacopeia (USP), include light obscuration (LO) and microscopic particle count tests. However, newer techniques such as flow imaging (FI) and BMI provide more\u00a0accurate\u00a0identification of particles and better characterization of their morphology.<sup>1<\/sup>\u00a0<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-large\"><img decoding=\"async\" width=\"741\" height=\"1024\" src=\"https:\/\/www.waters.com\/blog\/wp-content\/uploads\/image-32-741x1024.png\" alt=\"USP <788&gt;Drug-drug combination cumulative results for USP Method 1 and Method 2 \" class=\"wp-image-6713\" srcset=\"https:\/\/www.waters.com\/blog\/wp-content\/uploads\/image-32-741x1024.png 741w, https:\/\/www.waters.com\/blog\/wp-content\/uploads\/image-32-217x300.png 217w, https:\/\/www.waters.com\/blog\/wp-content\/uploads\/image-32-768x1061.png 768w, https:\/\/www.waters.com\/blog\/wp-content\/uploads\/image-32.png 903w\" sizes=\"(max-width: 741px) 100vw, 741px\" \/><figcaption class=\"wp-element-caption\">Figure 1. USP &lt;788> Drug-drug\u00a0combination\u00a0cumulative\u00a0results for USP Method 1 and Method 2. From: Ross et al., \u201cPhysical Compatibility of Y-site\u00a0Pediatric\u00a0Drug Administration: A Call for Question of US Pharmacopeia Standards?\u201d The Journal of\u00a0Pediatric\u00a0Pharmacology and Therapeutics, vol. 28, no. 1, 2023, p 84-92.<\/figcaption><\/figure>\n<\/div>\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full\"><img decoding=\"async\" width=\"903\" height=\"897\" src=\"https:\/\/www.waters.com\/blog\/wp-content\/uploads\/image-33.png\" alt=\"Drug-drug combinations by compatibility\" class=\"wp-image-6714\" srcset=\"https:\/\/www.waters.com\/blog\/wp-content\/uploads\/image-33.png 903w, https:\/\/www.waters.com\/blog\/wp-content\/uploads\/image-33-300x298.png 300w, https:\/\/www.waters.com\/blog\/wp-content\/uploads\/image-33-150x150.png 150w, https:\/\/www.waters.com\/blog\/wp-content\/uploads\/image-33-768x763.png 768w\" sizes=\"(max-width: 903px) 100vw, 903px\" \/><figcaption class=\"wp-element-caption\">Figure 2. Drug-drug\u00a0combinations by\u00a0compatibility. From: Ross et al., \u201cPhysical Compatibility of Y-site\u00a0Pediatric\u00a0Drug Administration: A Call for Question of US Pharmacopeia Standards?\u201d The Journal of\u00a0Pediatric\u00a0Pharmacology and Therapeutics, vol. 28, no. 1, 2023, p 84-92.<\/figcaption><\/figure>\n<\/div>\n\n<style>.wp-block-kadence-spacer.kt-block-spacer-6707_fbe78d-32 .kt-block-spacer{height:60px;}.wp-block-kadence-spacer.kt-block-spacer-6707_fbe78d-32 .kt-divider{border-top-width:1px;height:1px;border-top-color:#eee;width:80%;border-top-style:solid;}<\/style>\n<div class=\"wp-block-kadence-spacer aligncenter kt-block-spacer-6707_fbe78d-32\"><div class=\"kt-block-spacer kt-block-spacer-halign-center\"><hr class=\"kt-divider\"\/><\/div><\/div>\n\n\n<style>.wp-block-kadence-advancedheading.kt-adv-heading6707_07a88b-12, .wp-block-kadence-advancedheading.kt-adv-heading6707_07a88b-12[data-kb-block=\"kb-adv-heading6707_07a88b-12\"]{font-style:normal;}.wp-block-kadence-advancedheading.kt-adv-heading6707_07a88b-12 mark.kt-highlight, .wp-block-kadence-advancedheading.kt-adv-heading6707_07a88b-12[data-kb-block=\"kb-adv-heading6707_07a88b-12\"] mark.kt-highlight{font-style:normal;color:#f76a0c;-webkit-box-decoration-break:clone;box-decoration-break:clone;padding-top:0px;padding-right:0px;padding-bottom:0px;padding-left:0px;}.wp-block-kadence-advancedheading.kt-adv-heading6707_07a88b-12 img.kb-inline-image, .wp-block-kadence-advancedheading.kt-adv-heading6707_07a88b-12[data-kb-block=\"kb-adv-heading6707_07a88b-12\"] img.kb-inline-image{width:150px;vertical-align:baseline;}<\/style>\n<h2 class=\"kt-adv-heading6707_07a88b-12 wp-block-kadence-advancedheading\" data-kb-block=\"kb-adv-heading6707_07a88b-12\">Subvisible Particle Analysis via BMI\u00a0<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Particles in high quantities or those with large diameters have the potential to be more devastating in small infants and children compared with adults, due to smaller pulmonary capillary size and\u00a0relatively large\u00a0fluid intake relative to their body weight. Because of the administration challenges specific to\u00a0pediatric\u00a0patients and the clinical risk associated with particle infusions, FI and BMI instrumental methodologies were used to assess USP &lt;788> methods 1 and 2, despite a lack of precedent for either method in USP &lt;788> guidelines. In this evaluation, these two methods\u00a0demonstrated\u00a0much higher accuracy for\u00a0identifying\u00a0particulates in solution when compared with LO.<sup>1<\/sup>\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Applying USP &lt;788> methods clinically to\u00a0pediatric\u00a0pharmacy practice brings to light clinical and analytical controversies. Are current LO and microscopy methods the most\u00a0appropriate to\u00a0use to test the compatibility of medication combinations? Additionally, are the current USP\u00a0&lt;788> particle count thresholds still applicable given the increased particle detection rates of instrumental methods now available? The USP chapter offers no explanation as to where the existing particle count thresholds originated, why method 1 has particle count limits that are\u00a0essentially double\u00a0that of method 2, or why large-volume\u00a0parenterals\u00a0are held to a different standard when compared with small-volume\u00a0parenterals.<sup>1<\/sup><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Nevertheless, the team of researchers felt that results of incompatibility from any method used should\u00a0preclude\u00a0clinical use of a medicine combination for all patients, and for newborns and small\u00a0infants in particular.<sup>1<\/sup>\u00a0<\/p>\n\n\n<style>.wp-block-kadence-spacer.kt-block-spacer-6707_0b334d-25 .kt-block-spacer{height:60px;}.wp-block-kadence-spacer.kt-block-spacer-6707_0b334d-25 .kt-divider{border-top-width:1px;height:1px;border-top-color:#eee;width:80%;border-top-style:solid;}<\/style>\n<div class=\"wp-block-kadence-spacer aligncenter kt-block-spacer-6707_0b334d-25\"><div class=\"kt-block-spacer kt-block-spacer-halign-center\"><hr class=\"kt-divider\"\/><\/div><\/div>\n\n\n<style>.wp-block-kadence-advancedheading.kt-adv-heading6707_d0755b-90, .wp-block-kadence-advancedheading.kt-adv-heading6707_d0755b-90[data-kb-block=\"kb-adv-heading6707_d0755b-90\"]{font-style:normal;}.wp-block-kadence-advancedheading.kt-adv-heading6707_d0755b-90 mark.kt-highlight, .wp-block-kadence-advancedheading.kt-adv-heading6707_d0755b-90[data-kb-block=\"kb-adv-heading6707_d0755b-90\"] mark.kt-highlight{font-style:normal;color:#f76a0c;-webkit-box-decoration-break:clone;box-decoration-break:clone;padding-top:0px;padding-right:0px;padding-bottom:0px;padding-left:0px;}.wp-block-kadence-advancedheading.kt-adv-heading6707_d0755b-90 img.kb-inline-image, .wp-block-kadence-advancedheading.kt-adv-heading6707_d0755b-90[data-kb-block=\"kb-adv-heading6707_d0755b-90\"] img.kb-inline-image{width:150px;vertical-align:baseline;}<\/style>\n<h2 class=\"kt-adv-heading6707_d0755b-90 wp-block-kadence-advancedheading\" data-kb-block=\"kb-adv-heading6707_d0755b-90\">Conclusion\u00a0<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">\u00a0The study found that newer techniques such as BMI were more precise in\u00a0identifying\u00a0particulates, which raises questions about the applicability of current USP guidelines to\u00a0pediatric\u00a0pharmacy practice. While these findings signify steps forward in improving clinical results and reducing IV access requirements for\u00a0pediatric\u00a0patients, further chemical compatibility testing is still needed.<sup>1<\/sup>\u00a0<\/p>\n\n\n<style>.wp-block-kadence-spacer.kt-block-spacer-6707_d24980-10 .kt-block-spacer{height:60px;}.wp-block-kadence-spacer.kt-block-spacer-6707_d24980-10 .kt-divider{border-top-width:1px;height:1px;border-top-color:#eee;width:80%;border-top-style:solid;}<\/style>\n<div class=\"wp-block-kadence-spacer aligncenter kt-block-spacer-6707_d24980-10\"><div class=\"kt-block-spacer kt-block-spacer-halign-center\"><hr class=\"kt-divider\"\/><\/div><\/div>\n\n\n<style>.wp-block-kadence-advancedheading.kt-adv-heading6707_5d1956-a9, .wp-block-kadence-advancedheading.kt-adv-heading6707_5d1956-a9[data-kb-block=\"kb-adv-heading6707_5d1956-a9\"]{font-style:normal;}.wp-block-kadence-advancedheading.kt-adv-heading6707_5d1956-a9 mark.kt-highlight, .wp-block-kadence-advancedheading.kt-adv-heading6707_5d1956-a9[data-kb-block=\"kb-adv-heading6707_5d1956-a9\"] mark.kt-highlight{font-style:normal;color:#f76a0c;-webkit-box-decoration-break:clone;box-decoration-break:clone;padding-top:0px;padding-right:0px;padding-bottom:0px;padding-left:0px;}.wp-block-kadence-advancedheading.kt-adv-heading6707_5d1956-a9 img.kb-inline-image, .wp-block-kadence-advancedheading.kt-adv-heading6707_5d1956-a9[data-kb-block=\"kb-adv-heading6707_5d1956-a9\"] img.kb-inline-image{width:150px;vertical-align:baseline;}<\/style>\n<h2 class=\"kt-adv-heading6707_5d1956-a9 wp-block-kadence-advancedheading\" data-kb-block=\"kb-adv-heading6707_5d1956-a9\">References<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">1. Ross, Emma L., et al. \u201cPhysical Compatibility of Y-site\u00a0Pediatric\u00a0Drug Administration: A Call for Question of US Pharmacopeia Standards?\u201d The Journal of\u00a0Pediatric\u00a0Pharmacology and Therapeutics, vol. 28, no. 1, 2023, pp. 84-92,\u202f<a href=\"https:\/\/doi.org\/10.5863\/1551-6776-28.1.84\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.5863\/1551-6776-28.1.84<\/a>.\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Navigating the complex landscape of\u00a0pediatric\u00a0healthcare, particularly when it involves administering intravenous (IV) medication to children, brings about a unique set of difficulties. The task becomes even more daunting when dealing with critically ill patients who\u00a0frequently\u00a0require extensive IV drugs to\u00a0maintain\u00a0homeostasis.\u00a0 To put it into perspective, an infant in a neonatal intensive care unit might receive an&#8230;<\/p>\n","protected":false},"author":60,"featured_media":6708,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_seopress_titles_title":"%%post_title%% %%sep%% %%sitetitle%%","_seopress_titles_desc":"Learn about the complexities of administering intravenous (IV) medication to children, especially with changing US Pharmacopeia Standards like USP 788.","_seopress_robots_index":"","_seopress_robots_follow":"","_seopress_robots_imageindex":"","_seopress_robots_snippet":"","_seopress_robots_primary_cat":"none","_seopress_robots_breadcrumbs":"","_seopress_robots_freeze_modified_date":"","_seopress_robots_custom_modified_date":"","_seopress_robots_canonical":"","_seopress_social_fb_title":"","_seopress_social_fb_desc":"","_seopress_social_fb_img":"","_seopress_social_fb_img_attachment_id":0,"_seopress_social_fb_img_width":0,"_seopress_social_fb_img_height":0,"_seopress_social_twitter_title":"","_seopress_social_twitter_desc":"","_seopress_social_twitter_img":"","_seopress_social_twitter_img_attachment_id":0,"_seopress_social_twitter_img_width":0,"_seopress_social_twitter_img_height":0,"_seopress_redirections_value":"","_seopress_redirections_enabled":"","_seopress_redirections_enabled_regex":"","_seopress_redirections_logged_status":"both","_seopress_redirections_param":"","_seopress_redirections_type":301,"_seopress_analysis_target_kw":"usp 788,iv drugs,particulate matter in injectable products,subvisible particle analysis","_seopress_news_disabled":"","_seopress_video_disabled":"","_seopress_video":[],"_seopress_pro_schemas_manual":[],"_seopress_pro_rich_snippets_disable_all":"","_seopress_pro_rich_snippets_disable":[],"_seopress_pro_schemas":[],"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"categories":[228,1],"tags":[742,741,722,744,743,740,728],"class_list":["post-6707","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharmaceutical","category-general","tag-iv-drugs","tag-iv-medication","tag-particle-analysis","tag-particulate-matter","tag-pediatric-healthcare","tag-pharmacopeia-standards","tag-usp-788"],"acf":[],"taxonomy_info":{"category":[{"value":228,"label":"Biopharmaceutical"},{"value":1,"label":"General"}],"post_tag":[{"value":742,"label":"IV drugs"},{"value":741,"label":"IV medication"},{"value":722,"label":"particle analysis"},{"value":744,"label":"particulate matter"},{"value":743,"label":"pediatric healthcare"},{"value":740,"label":"pharmacopeia standards"},{"value":728,"label":"usp 788"}]},"featured_image_src_large":["https:\/\/www.waters.com\/blog\/wp-content\/uploads\/image-29.png",600,426,false],"author_info":{"display_name":"Donald Mason","author_link":"https:\/\/www.waters.com\/blog\/author\/dmason\/"},"comment_info":"","category_info":[{"term_id":228,"name":"Biopharmaceutical","slug":"biopharmaceutical","term_group":0,"term_taxonomy_id":228,"taxonomy":"category","description":"We help ensure the medicines people take every day are reliably safe and effective, from the common aspirin to the most complex biotherapy. Tests performed using our liquid chromatography-mass spectrometry (LC-MS) instruments ensure the efficacy and safety of these complex, protein-based drugs well before they reach the patient.","parent":25,"count":42,"filter":"raw","term_order":"0","cat_ID":228,"category_count":42,"category_description":"We help ensure the medicines people take every day are reliably safe and effective, from the common aspirin to the most complex biotherapy. Tests performed using our liquid chromatography-mass spectrometry (LC-MS) instruments ensure the efficacy and safety of these complex, protein-based drugs well before they reach the patient.","cat_name":"Biopharmaceutical","category_nicename":"biopharmaceutical","category_parent":25},{"term_id":1,"name":"General","slug":"general","term_group":0,"term_taxonomy_id":1,"taxonomy":"category","description":"","parent":0,"count":52,"filter":"raw","term_order":"0","cat_ID":1,"category_count":52,"category_description":"","cat_name":"General","category_nicename":"general","category_parent":0}],"tag_info":[{"term_id":742,"name":"IV drugs","slug":"iv-drugs","term_group":0,"term_taxonomy_id":742,"taxonomy":"post_tag","description":"","parent":0,"count":1,"filter":"raw","term_order":"0"},{"term_id":741,"name":"IV medication","slug":"iv-medication","term_group":0,"term_taxonomy_id":741,"taxonomy":"post_tag","description":"","parent":0,"count":1,"filter":"raw","term_order":"0"},{"term_id":722,"name":"particle analysis","slug":"particle-analysis","term_group":0,"term_taxonomy_id":722,"taxonomy":"post_tag","description":"","parent":0,"count":21,"filter":"raw","term_order":"0"},{"term_id":744,"name":"particulate matter","slug":"particulate-matter","term_group":0,"term_taxonomy_id":744,"taxonomy":"post_tag","description":"","parent":0,"count":1,"filter":"raw","term_order":"0"},{"term_id":743,"name":"pediatric healthcare","slug":"pediatric-healthcare","term_group":0,"term_taxonomy_id":743,"taxonomy":"post_tag","description":"","parent":0,"count":1,"filter":"raw","term_order":"0"},{"term_id":740,"name":"pharmacopeia standards","slug":"pharmacopeia-standards","term_group":0,"term_taxonomy_id":740,"taxonomy":"post_tag","description":"","parent":0,"count":1,"filter":"raw","term_order":"0"},{"term_id":728,"name":"usp 788","slug":"usp-788","term_group":0,"term_taxonomy_id":728,"taxonomy":"post_tag","description":"","parent":0,"count":3,"filter":"raw","term_order":"0"}],"_links":{"self":[{"href":"https:\/\/www.waters.com\/blog\/wp-json\/wp\/v2\/posts\/6707","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.waters.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.waters.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.waters.com\/blog\/wp-json\/wp\/v2\/users\/60"}],"replies":[{"embeddable":true,"href":"https:\/\/www.waters.com\/blog\/wp-json\/wp\/v2\/comments?post=6707"}],"version-history":[{"count":0,"href":"https:\/\/www.waters.com\/blog\/wp-json\/wp\/v2\/posts\/6707\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.waters.com\/blog\/wp-json\/wp\/v2\/media\/6708"}],"wp:attachment":[{"href":"https:\/\/www.waters.com\/blog\/wp-json\/wp\/v2\/media?parent=6707"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.waters.com\/blog\/wp-json\/wp\/v2\/categories?post=6707"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.waters.com\/blog\/wp-json\/wp\/v2\/tags?post=6707"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}